Videos

The director of vascular neurology at NYU Langone Hospital in Brooklyn discussed the high prevalence of common risk factors for stroke, emphasizing the importance of early detection and management for prevention. [WATCH TIME: 4 minutes]

The associate professor at the University of Colorado highlighted the limitations of standard care visits in collecting crucial data from pediatric multiple sclerosis centers. [WATCH TIME: 3 minutes]

The head of CRCSEP and coordinator of the Neurosciences Research Unit at Paris City University discussed the positive results of teriflunomide in treating radiologically isolated syndrome, a preclinical stage of multiple sclerosis. [WATCH TIME: 4 minutes]

Expert neurologists discuss treatment options for a patient with comorbid autoimmune diseases, relapsing/remitting multiple sclerosis, and psoriasis.

Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, review the use of rituximab and other disease-modifying therapies in a patient with an established diagnosis of relapsing/remitting multiple sclerosis.

Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences.

Experts discuss sodium oxybate and antidepressants for treatment of cataplexy.

Experts discuss the efficacy and safety profile of solriamfetol for the treatment of narcolepsy.

The director of the James J. and Joan A. Gardner Family Center discussed data from the phase 3 BouNDless trial assessing a continuous, subcutaneous levodopa/carbidopa delivery system for patients with Parkinson disease experiencing motor fluctuations. [WATCH TIME: 3 minutes]

The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute discussed the future of treating Parkinson disease psychosis, and potential ways to lower risk of poor long-term outcomes. [WATCH TIME: 3 minutes]

Episode 34 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Merit Cudkowicz, MD, of Mass General Hospital and Harvard Medical School. [WATCH TIME: 4 minutes]

The consultant and founder of Accelerating NeuroVentures talked about the pridopidine arm from the HEALEY ALS Platform trial, which showed significant benefits in speech measures. [WATCH TIME: 5 minutes]

The director of vascular neurology at NYU Langone talked about how to identify the signs and symptoms of stroke and the importance of early intervention. [WATCH TIME: 4 minutes]

The senior academic at the University of Sydney provided perspective on the role of CNM-Au8 in MS among a crowded treatment landscape, and the need for adjuvant treatments that address lingering lesion burden. [WATCH TIME: 3 minutes]

The chief executive officer of Cognixion talked about the Cognixion ONE Axon, a wireless, wearable brain-computer interface that combines EEG technology with an augmented reality headset for patients with neurodegenerative diseases. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending May 20, 2023. [WATCH TIME: 4 minutes]

The assistant professor of neurology at the University of North Carolina at Chapel Hill discussed the importance of recognizing disability as part of diversity in neurology, emphasizing the need for inclusive communication and accessibility for disabled patients. [WATCH TIME: 10 minutes]

The associate professor of neurology at Albert Einstein College of Medicine talked about a review on neonatal seizures recently published in the New England Journal of Medicine. [WATCH TIME: 5 minutes]

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided commentary on the possibility of preventing NMOSD, and the need to improve access to approved therapies and AQP4 testing. [WATCH TIME: 3 minutes]

Bruce Hughes, MD, comments on the current use and access to biomarkers in MS management, as well as sharing how NfL is being used in clinical practice presently.

An expert neurologist discusses pNfL being utilized outside of clinical trials and implemented into clinical practice for the treatment of MS.

Bruce Hughes, MD, reviews clinical trials of use of NfL in MS, highlighting data on the Bruton’s tyrosine kinase inhibitor, evobrutinib.

Bruce Hughes, MD, provides an overview of the use of neurofilament light chain (NfL) as a biomarker in multiple sclerosis (MS), highlighting the accuracy and reliability of plasma/serum NfL (pNfL) and cerebrospinal fluid (CSF) NfL measurements.

The associate professor at the University of Colorado talked about a study involving pediatric patients with multiple sclerosis and related disorders, and the risk of COVID-19 infection among those on B-cell-depleting therapy. [WATCH TIME: 5 minutes]

Anne Marie Morse, DO, FAASM, discusses the efficacy and safety profile of pitolisant for the treatment of narcolepsy.

Thomas E. Scammell, MD, provides an overview of the mechanism of action of pitolisant for the treatment of narcolepsy.

The neurology PGY-3 at Mayo Clinic in Arizona talked about findings from a retrospective cohort study that examined blood pressure in patients who were prescribed a migraine medication. [WATCH TIME: 6 minutes]

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, discuss a patient case with relapsing/remitting multiple sclerosis progression and share considerations for switching treatment.

Expert neurologists review treatment options for a young female with relapsing remitting multiple sclerosis (RRMS).

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided insight on the necessary research needed to understand why certain races experience more significant multiple sclerosis disease progress. [WATCH TIME: 4 minutes]